Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A

Ultrasound in Obstetrics and Gynecology

Volumn 31, Issue 6, 2008, Pages 618-624

  Kagan, K O ^a,c   Wright, D ^b   Baker, A ^b   Sahota, D ^d   Nicolaides, K H ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

First trimester screening; Free hCG; Nuchal translucency; PAPP A; Trisomy 21

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADOLESCENT; ADULT; ARTICLE; BLOOD ANALYSIS; COMPARATIVE STUDY; CONCEPTION; CONTROLLED STUDY; ETHNICITY; FEMALE; FETUS MALFORMATION; FIRST TRIMESTER PREGNANCY; GESTATIONAL AGE; HUMAN; KARYOTYPE; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MATERNAL AGE; MONTE CARLO METHOD; NORMAL DISTRIBUTION; NUCHAL TRANSLUCENCY MEASUREMENT; PARITY; PREGNANCY; PRIORITY JOURNAL; SCREENING; SMOKING; TRISOMY 21;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DOWN SYNDROME; FEMALE; GESTATIONAL AGE; HUMANS; LIKELIHOOD FUNCTIONS; MATERNAL AGE; MIDDLE AGED; NUCHAL TRANSLUCENCY MEASUREMENT; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; RISK;

EID: 51949091028     PISSN: 09607692     EISSN: 14690705     Source Type: Journal    
DOI: 10.1002/uog.5331     Document Type: Article

References (19)

1. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk of trisomy 21 by maternal age and fetal nuchal-translucency thickness at 10-14 weeks of gestation. Lancet 1998; 352: 343-346.
2. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231-237.
3. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening. Ultrasound Obstet Gynecol 2005; 25: 221-226.
4. Nicolaides KH. Nuchal translucency and other first-trimester sonographic markers of chromosomal abnormalities. Am J Obstet Gynecol 2004; 191: 45-67.
5. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008; 31: 376-383.
6. Kagan KO, Wright D, Spencer K, Molina FS, Nicolaides KH. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31: 493-502.
7. rd edn). Wiley: New York, NY, 1998.
8. Cuckle HS, Wald NJ, Thompson SG. Estimating a woman's risk of having a pregnancy associated with Down's syndrome using her age and serum alpha-fetoprotein level. Br J Obstet Gynaecol 1987; 94: 387-402.
9. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age- and gestation-specific risk for trisomy 21. Ultrasound Obstet Gynecol 1999; 13: 167-170.
10. Office for National Statistics. Birth Statistics. Review of the Registrar General on births and patterns of family building in England and Wales. Series FM1, number 29-31. Stationery Office: London, 2000-2002.
11. National Screening Committee. National Screening Committee Policy - Down's Syndrome Screening (compiled July 2006). http://www.library.nhs.uk/ screening/ViewResource.aspx?resID=35689 [Accessed 23 December 2007].
12. Cuckle H, Benn P, Wright D. Down syndrome screening in the first and/or second trimester: model predicted performance using meta-analysis parameters. Semin Perinatol 2005; 29: 252-257.
13. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM; SURUSS Research Group. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003; 7: 1-77.
14. Malone FD, Canick JA, Ball RH, Nyberg DA, Comstock CH, Bukowski R, Berkowitz RL, Gross SJ, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Dukes K, Bianchi DW, Rudnicka AR, Hackshaw AK, Lambert-Messerlian G, Wald NJ, D'Alton ME; First- and Second-Trimester Evaluation of Risk (FASTER) Research Consortium. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353: 2001-2011.
15. Souka AP, Pilalis A, Kavalakis Y, Kosmas Y, Antsaklis P, Antsaklis A. Assessment of fetal anatomy at the 11-14-week ultrasound examination. Ultrasound Obstet Gynecol 2004; 24: 730-734.
16. Cicero S, Curcio P, Papageorghiou A, Sonek J, Nicolaides K. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study. Lancet 2001; 358: 1665-1667.
17. Sonek J, Borenstein M, Dagklis T, Persico N, Nicolaides KH. Frontomaxillary facial angle in fetuses with trisomy 21 at 11-13(6) weeks. Am J Obstet Gynecol 2007; 196: 271.e1-271.e4.
18. Matias A, Gomes C, Flack N, Montenegro N, Nicolaides KH. Screening for chromosomal abnormalities at 11-14 weeks: the role of ductus venosus blood flow. Ultrasound Obstet Gynecol 1998; 2: 380-384.
19. Faiola S, Tsoi E, Huggon IC, Allan LD, Nicolaides KH. Likelihood ratio for trisomy 21 in fetuses with tricuspid regurgitation at the 11 to 13 + 6-week scan. Ultrasound Obstet Gynecol 2005; 26: 22-27.